# Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

> **NCT01282255** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 67 (actual)

## Conditions studied

- Inflammation
- Rheumatoid Arthritis

## Interventions

- **DRUG:** NNC109-0012
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01282255
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282255, "Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01282255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*